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Lead chelation therapy and urate excretion in patients with with chronic high-level lead exposures [1, 2], it is unclear
chronic renal diseases and gout. whether chronic low-level environmental lead exposures
Background. It is known that chronic renal insufficiency have the same effects on the general population with(CRI) patients with gout may have subtle lead poisoning. In
chronic renal diseases. In the past, only a few articlesaddition, gout episodes frequently aggravate progressive renal
have described a correlation between serum urate andinsufficiency because of the use of nephrotoxic drugs and urate
deposition. Our study was arranged to evaluate the causal blood lead levels (BLL) [6–8]. However, the BLL is only
effect of environmental lead exposure on urate excretion in an index of recent lead exposure and not an index of
CRI patients.
total body lead stores (BLS). In addition, related factors,Methods. A cross-section study and a randomized, controlled
for example, creatinine clearance (CCr), were not ad-trial were performed. Initially, 101 patients with CRI and without
a history of previous lead exposure received ethylenediamine- justed in those studies. Although previous reports sug-
tetraacetic acid mobilization tests to assess body lead stores gested that chronic renal insufficiency (CRI) patients
(BLS). Then, a clinical trial was performed; 30 CRI patients with gout had subtle lead poisoning [6–8] or higher BLSwith gout and high-normal BLS and the changes of urate excre-
[9, 10], the causal effect of lead on urate excretion is stilltion in these patients were compared before and after lead chelat-
unclear. In clinical practice, gout episodes frequentlying therapy. The treated group received four-week chelating
therapy, and the control group received a placebo therapy. aggravate the progression of renal insufficiency in these
Results. The BLS of patients with CRI and gout was higher patients because of the use of nephrotoxic anti-inflam-
than that of patients with CRI only, and none had subtle lead
matory drugs and urate deposition on the kidneys. Hence,poisoning. The BLS, not the blood lead level (BLL), significantly
it is important to clarify the causal effect of lead oncorrelated to indices of urate excretion in all CRI patients after
related factors were adjusted. In addition, after lead chelating inhibition of urate excretion in CRI patients.
therapy, urate clearance markedly improved after a reduction This prospective study was designed to determine
of the BLS of patients with CRI and gout (study group 67.9  whether chronic low-level environmental lead exposure80.0% vs. control group 1.2  34.0%, P  0.0056).
affects urate excretion in patients with CRI and whetherConclusion. Our findings suggest that the chronic low-level
the removal of body lead increases urate excretion.environmental lead exposure may interfere with urate excretion
of CRI patients. Importantly, the inhibition of urate excretion
can be markedly improved by lead chelating therapies. These
data shed light on additional treatment of CRI patients with METHODS
gout; however, more studies are needed to confirm our findings. This prospective study was conducted during a one-
year period. The study was approved by the Medical
Ethics Committee of Chang Gung Memorial Hospital,
Lead is one of the main environmental pollutants, and all of the patients gave their informed consent.
despite its well-established toxic properties and precau-
tions taken during its use [1–5]. Although gout and im- Patients
paired renal function have been observed in the workers
One hundred fifty adults with CRI [serum creatinine
(SCr)1.5 mg/dL and3.0 mg/dL] followed at our nephro-
logic outpatient department for at least six months wereKey words: environmental lead exposure, chronic renal insufficiency,
nephrotoxicity, pollutant, serum urate. included in our study. Renal diseases were diagnosed from
the results of the patient’s history, laboratory evaluations,
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initial renal biopsy reports, persistent severe proteinuria Randomly controlled clinical trial
(2 g/day) prerenal function impairment and postrenal A randomly controlled chelating trial was performed
function impairment or persistent nephritic syndrome to clarify the role of lead in urate excretion after the
(microhematuria with red blood cell casts and protein- cross-sectional survey. Thirty CRI patients with gout and
uria 1 g/day). Essential hypertension-related nephrop- high-normal BLS were randomly divided into two groups
athy was diagnosed by a renal biopsy or as determined on the proportion 2:1. The study group (N  20) and
in our previous work [11]. The criteria of essential hyper- the control group (N  10) were divided according to a
tension-related nephropathy for inclusion required that randomly digitized method in which the random num-
the clinical diagnosis of essential hypertension precede bers came directly from the computer software program.
the onset of CRI. In addition, every patient had been The high-normal BLS was defined as greater than the
followed up at our hospital and had complete medical mean (64.2g) BLS of the CRI group patients. Informed
records for at least eight years that demonstrated a his- consent forms were obtained from all patients. The study
tory of hypertension preceding the clinical identification group patients received a weekly intravenous infusion
of renal function impairment by 8 to 21 years. Patients of 1 amp (1 g) of calcium disodium ethylenediaminetetra-
without diabetes mellitus who could not be classified to acetic acid (EDTA) mixed with 200 mL normal saline
any definite etiology of CRI, including CGN, essential for over two hours for four weeks. BLS was measured
hypertension-related nephropathy, polycystic kidney again at the end of chelating therapy. The control group
disease, obstructive uropathy, lupus nephritis, or analge- patients received a weekly intravenous infusion of 1 amp
sia nephropathy, were classified as “unknown causes.” (20 mL) 50% glucose as a placebo, in 200 mL normal
Gouty arthritis was diagnosed by our rheumatologist saline for over two hours for four weeks. The injected
based on monosodium urate crystal in the synovial fluid drugs were mixed in the pharmacy room. None of the
or a history of podogra, abrupt onset and remission patients knew which drugs they received. The treatment
within two weeks, and at least two or more attacks [12]. course was set four weeks according to the experience
The patients with a definite history of a gout episode of our previous studies [17, 18]. In addition, the CCr andafter CRI recorded in the medical chart were included indices of urate excretion of both groups were measured
in this study, even those with inactive gout for several
at the end of chelating therapy. Three consecutive 24-
years. All patients with diabetes mellitus, alcoholism,
hour urine collections were obtained from each patient
nephrotic syndrome, primary gout prior to CRI [1], preg-
and were analyzed for creatinine and urate. The resultsnancy, family histories of gout, or known histories of
of CCr, UurateE, Curate, and FEurate were expressed as thelead exposure were excluded. Medication affecting urate
arithmetic means of the three collections.metabolism or renal function, including alcohol, cimeti-
dine, diuretics, and nonsteroid anti-inflammatory drugs Assessment of body lead store
had been discontinued in all patients for at least four
Body lead stores were determined using the protocolweeks prior to and during the study period [6–8]. All
developed by Emmerson and modified by Behringer etpatients received a dietary consultation and avoided a
al [19]. On the first day of the study, each patient emptiedhigh purine diet for at least three days before uric acid
his bladder and then received an intravenous infusionwas checked. The 24-hour urine urea excretion was mea-
of 1 g of calcium disodium EDTA mixed with 200 mLsured to assess daily protein intake [13].
5% dextrose in water over two hours. The patients were
requested to collect a 24-hour urine in 2 L lead-free bottlesLaboratory evaluations
over three consecutive days on an outpatient basis. TheBlood chemistries were analyzed using routine labora-
total amount of urine lead collected over three days (72tory methods using an autoanalyzer (Model 736; Hitachi,
hours) was considered the BLS. Daily urine amount wasTokyo, Japan). Three consecutive 24-hour urine collec-
collected by spontaneous voiding. The patients were hy-tions were obtained from each patient and analyzed for
drated orally with water in amounts sufficient to providecreatinine and urate. The method for the determination
a steady rate of urine flow of at least 1 mL/min. Anyof creatinine in blood and urine samples was based on
patients without an accurate urine collection (more thanthe Jaffe reaction [14]. Urate in both serum and urine
1 lost urine collection) or inadequate urine flow (lesswas measured by automated colorimetric procedures us-
than 4500 mL during the 3-day collection) were excluded.ing an uricase peroxidase system [15]. Creatinine clear-
ance (CCr), daily excretion of urate (UurateE), urate clear-
Measurement of leadance (Curate), and fractional excretion of urate (FEurate;
The samples were assessed at the Chang Gung Memo-calculated as Curate/CCr  100) were calculated using stan-
rial Hospital by using electrothermal atomic absorptiondard formulae [16]. The results of CCr, UurateE, Curate, and
spectrometry (Perkin-Elmer 5100 PC, Norwalk, CT, USA)FEurate were expressed as the arithmetic means of the
three collections. with a Zeeman background correction and L’vov plat-
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Table 1. Characteristics of patients (N  101) in the two study groups: Chronic renal insufficiency only (CRI) and CRI plus gout
CRI only CRI and gout
(N34) (N67) P
Age years 56.111.6 (36–79) 55.111.2 (34–71) 0.6666
Sex 25M 9F 52M 15F 0.6317a
Body mass index kg/m2 24.72.9 (20.2–32.5) 25.12.7 (17.1–30.5) 0.5044
Daily protein intake g/kg/day 1.000.15 (0.69–1.40) 1.030.24 (0.58–1.89) 0.4329
Creatinine clearance mL/min 50.818.2 (24.0–100) 50.416.3 (16.2–86.3) 0.9123
Blood lead levels lg/dL 4.391.87 (1.2–7.6) 5.363.12 (1.2–12.5) 0.0988
Body lead store lg 64.245.6 (5.2–216.4) 138.1116.6 (3.6–545) 0.0006
Serum urate mg/dL 8.61.6 (5.4–14.3) 9.92.1 (5.1–15.5) 0.0018
Daily urate excretion mg/day 536.7182.5 (207–975) 452.7200.9 (95–1056) 0.0439
Urate clearance mL/min 4.401.62 (1.92–8.10) 3.391.85 (0.73–8.80) 0.0079
Fractional urate excretion % 9.44.4 (4.0–23.0) 7.43.9 (1.0–25.9) 0.0199
Underlying renal disease
CGN 16 24 0.5170a
HT 5 10 0.9999a
Analgesia 4 6 0.5179a
PKD 2 4 0.9999a
Lupus 1 2 0.9999a
Unknown 9 21 0.6457a
Abbreviations are: CRI, chronic renal insufficiency with serum creatinine 1.5 and 3.0 mg/dL; CGN, chronic glomerulonephritis; HT, essential hypertension-
related nephropathy; Lupus, lupus nephropathy; PKD, polycystic kidney disease; Analgesia, analgesic nephropathy; Unknown, renal disease with unknown origins.
a As measured by the Chi-square with Fisher’s test
form [19]. All lead determinations were performed at during the study period, 14 patients with inaccurate urine
least in duplicate. Throughout this study, both internal collection or inadequate urine flow, 11 patients with pri-
and external quality control procedures were used, with mary gout prior to CRI, and 3 patients with loss follow-
consistently satisfactory results. A certified, commercially up were excluded. A total of 101 patients with CRI was
prepared product (Seronorm Trace Elements, Sero AS, surveyed in this study. Table 1 lists the characteristics
Billingstads, Norway) was used to monitor intrabatch of the CRI patients and the CRI patients with gout. No
accuracy and ensure interbatch standardization. The co- patient had a BLS of more than 600 g. There were no
efficient of variation for lead measurement was 5.3% or significant differences of age, sex, body mass index, daily
less. External quality control was maintained by partici- protein intake, BLL, CCr, and underlying diseases be-
pation in two major programs: the National Quality- tween the two study groups. Serum urate levels and BLS
Control Program conducted by the government and the of CRI patients with gout were significantly higher than
international program run by the College of American those of the CRI group. Daily urate excretion, urate
Pathologists. Since anemia influences the measurement clearance, and fractional excretion of urate values of the
of blood lead, BLLs of study patients were calculated CRI patients with gout were significantly lower than
from the formula: BLL initial BLL 15 (g/dL)/patient’s those of the CRI patient group. In a simple linear regres-
hemoglobin (g/dL). Hemoglobin was evaluated by using sion analysis, BLL positively correlated with the BLS
a computerized Sysmex counter (Sysmex, Kobe, Japan). (r  0.532, P  0.0001) and Surate (r  0.222, P  0.0258)
in all patients; however, BLL did not correlate with dailyStatistical analysis
UurateE (r  0.166, P  0.0980), Curate (r  0.154, P Comparisons between groups were made with the Stu- 0.1240), and FEurate (r  0.106, P  0.2928). However,dent t test, Mann–Whitney U test, and 	2 with Fisher BLS positively correlated with Surate (r  0.457, P tests. Comparisons within each group were made with a 0.0001) but negatively with daily UurateE (r  0.375,paired Student t test before and after lead chelation
P  0.0001), Curate (r  0.436, P  0.0001), and FEuratetherapy. A P value 0.05 was considered to be statisti-
(r  0.365, P  0.0002) in all CRI patients (N  101).cally significant. Stepwise and multiple linear regression
In a stepwise regression analysis to assess age, sex, bodyanalyses were used to measure correlations between vari-
mass index, daily protein intake, CCr, and BLS, the BLSables. A P value 0.05 was considered statistically sig-
value was the most significant factor in determining uratenificant for a correlation. Data in this study are presented
clearance.as mean  SD.
Table 2 reveals the correlations between indices of
lead and urate excretion in all CRI patients (N  101)
RESULTS after age, sex, body mass index, daily protein intake, and
CCr were adjusted using multiple linear regression. BLLTwenty-one patients who took drugs affecting urate
metabolism or renal function four weeks prior to and did not correlate with Surate, daily UurateE, FEurate, and Curate
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Table 2. Relationships between indices of lead and urate excretion [19–21]. The mean BLL level in our study was similar
in the patients with chronic renal insufficiency after age, sex,
to that of recent studies in European and Americanbody mass index, daily protein intake and creatinine
clearance were adjusted (N  101) populations [3, 4]. CRI patients with gout had a higher
BLS and a lower urate clearance than those of patientsVariable 
 coefficientsSE P
with CRI only, although none of them had subtle lead
Correlation with blood lead levels
poisoning. These findings suggest that chronic environ-Serum urate mg/dL 0.1310.076 0.0858
Daily urate excretion mg 8.256.73 0.2235 mental lead exposures, even at low levels, influence the
Urate clearance mL/min 0.0520.063 0.4200 urate excretion of patients with chronic renal diseases.
Fractional urate excretion % 0.0020.001 0.1155
In addition, the markedly increasing urate excretion afterCorrelation with body lead stores
Serum urate mg/dL 0.0090.002 0.0001 lead chelating therapies suggests that the lead chelating
Daily urate excretion mg 0.6360.189 0.0011 therapy may be an effective alternative treatment for
Urate clearance mL/min 0.0070.002 0.0001
CRI patients with gout.Fractional urate excretion % 0.00020.00004 0.0001
To our knowledge, Campbell et al were the first toA P value 0.05 shows significant correlation in multiple linear regression
analysis. suggest an association between hyperuricemia and BLL
in patients without a history of overt lead exposure [7].
In contrast, Baker et al failed to find a relationship [8].
after adjusting related variables. However, BLS signifi- The controversy may be due to the small sample size in
cantly correlated with Surate, daily UurateE, Curate, and FEurate. their studies. In the British Regional Heart Study, after
Table 3 shows the basal data of the study and control allowing for the influence of alcohol consumption, there
groups who had a high-normal BLS level. There were was a weakly positive correlation between serum urate
no significant differences in age, sex, body mass index, and low BLL (37g/dL) in 7364 middle-aged men from
daily protein intake, BLL, BLS, CCr, and underlying renal 24 British towns [6]. While the finding of a relationship
disease between the two study group patients. between BLL and serum urate is in agreement with the
Table 4 shows CCr, daily protein intakes, and the indi- results of our current work, neither study assessed BLS
ces of urate excretion of the study and control group nor were the related factors adjusted statistically.
patients before and after lead chelating therapy. The Batuman et al [20] and Sanchez-Fructuoso et al [22]
BLS of the study patients significantly decreased to reported that there was greater excretion of chelatable
41.0  31.6 g after the EDTA chelating treatment. urinary lead levels in the patients with renal failure and
Between the two groups, there was less serum urate and gout. The mean BLS values of their study patients
there was a greater fractional urate excretion in the study (444 g [20], 671.5 g [22]) were approximately 3.4 and
group patients than the control group after chelating 5.0 times greater than that of our patients (138.1 g)
therapy. Similarly, within the study group, there was less because they did not completely exclude the patients
Surate (P  0.0047) and greater daily UurateE (P  0.0049), with alcohol (moonshine) ingestion or lead poisoning in
Curate (P  0.0018), and FEurate (P  0.0057) after the their analyses. In addition, in those studies no attempt
chelating therapy, and marginally greater CCr (P  to assess relationship between indices of urate excretion
0.0623) was noted. and BLS is mentioned. In another study, Reynolds et al
failed to find a relationship between BLS and hyperuri-The changes (%) of CCr, daily protein intakes, and
cemia in gout patients with chronic renal disease, sinceindices of urate excretion after the chelating therapies
their patient cohort included those with diabetes melli-are noted on Table 5. There were significant decreases
tus, alcoholism, and moonshine ingestion [23]. Based onof Surate and increases of daily UurateE, Curate, and FEurate in
these reasons, our current work may provide a morethe study group versus those of the control group patients
definite conclusion about the relationship between urateafter the chelating therapy, even though borderline sig-
and chronic low-level environmental lead exposure innificant changes of CCr were noted.
patients with CRI.
Our randomly controlled clinical trial first demon-
DISCUSSION strated that there was an increase of urate clearance
Our study demonstrates that BLS, not BLL, is associ- (67.9%) and fractional excretion of urate (55.6%) in the
ated with indices of urate excretion after related factors CRI patients with high-normal BLS, although a border-
were adjusted, although BLL initially correlated with line significant increase of their CCr (8.0%, P  0.0646)
serum urate. In addition, BLS, not CCr, was the most was found after the lead chelating therapies. In contrast,
important factor in determining urate clearance in all of no significant changes of renal function and indices of
the CRI patients. The mean BLL and BLS of our patients urate excretion were noted in the control group patients.
were only 4.62 g/dL and 113.2 g, which were far less The results clarify the causal effect of environmental
than the “safe” values (20 g/dL of BLL and 600 g lead exposure on urate excretion, and importantly, show
that the impairment of urate excretion can be treatedof BLS) found in studies of other general populations
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Table 3. Characteristics of patients with lead chelating therapy (N  30)
Variable Study group (N  20) Control group (N 10) P
Age years 53.411.9 (34–72) 54.310.4 (37–68) 0.8324
Sex 16M 4F 7M 3F 0.8787
Body mass index kg/m2 24.53.0 (20.4–31.2) 23.64.0 (16.4–31.2) 0.5113
Creatinine clearance mL/min 50.814.6 (23–81.2) 47.717.9 (17.4–70.0) 0.6100
Daily protein intake g/kg/day 0.950.18 (0.63–1.38) 0.960.21 (0.60–1.25) 0.8644
Blood lead levels lg/dL 5.962.46 (2.1–10.8) 6.704.23 (2.8–15.7) 0.3342
Body lead store lg 159.271.4 (80.2–361) 133.767.0 (80.6–262) 0.3536
Underlying renal disease
CGN 8 5 0.7055
HT 2 1 0.9999
Analgesia 3 1 0.9999
Unknown 7 3 0.9999
Abbreviations are: CGN, chronic glomerulonephritis (including IgA nephropathy); HT, essential hypertension-related nephropathy; Analgesia, analgesic nephropa-
thy; Unknown, renal disease with unknown origin. A P value 0.05 means significant differences.
Table 4. Means creatinine clearance and serum urate values, and indices of urate excretion between the control and study group patients
before and after four weeks of lead chelating therapy
Variable Study (N  20) Control (N  10) P 95% CI interval
Daily protein intake g/kg/day
Pre-chelation 0.950.18 0.960.21 0.8644 0.16–0.14
Post-chelation 0.970.15 1.010.15 0.4426 0.16–0.07
Creatinine clearance mL/min
Pre-chelation 50.814.6 47.717.9 0.6100 9.3–15.6
Post-chelation 54.215.0 46.517.4 0.2173 4.8–20.3
Serum urate mg/dL
Pre-chelation 10.21.7 10.31.8 0.8896 1.5–1.3
Post-chelation 8.61.9b 10.51.5 0.0091 3.3–5.1
Daily urate excretion mg
Pre-chelation 385.3130.3 385.0178.7 0.9958 116.8–117.4
Post-chelation 508.6207.6b 359.0170.9 0.0594 6.3–305.5
Urate clearance mL/min
Pre-chelation 2.660.97 2.701.40 0.9374 0.93–0.86
Post-chelation 4.221.92b 2.450.93 0.0841 0.45–3.09
Fractional urate excretion %
Pre-chelation 5.52.5 5.51.2 0.9754 1.7–1.7
Post-chelation 8.03.7a 5.51.4 0.0485 0.07–5.0
A P value 0.05 means significant differences by the Student t test between the study and control group patients. CI is confidence interval.
a P  0.05 and b P  0.005 by the paired t test within the study group patients before and after chelation therapy
Table 5. Changes (%) of serum urate and indices of urate excretion between the control and study group patients
after four weeks of lead chelating therapies
Changes of variable Study (N  20) Control (N  10) P 95% CI interval
Daily protein intake % 2.49.5 5.613.4 0.3116 11.9–5.5
Creatinine clearance % 8.015.0 1.86.3 0.0646 0.4–20.1
Serum urate % 22.432 1.416.7 0.0197 46.0–1.5
Daily urate excretion % 40.658.5 3.450.0 0.0155 7.2–81.5
Urate clearance % 67.980.0 1.234.0 0.0056 12.2–121.2
Fractional urate excretion % 55.671.7 2.429.7 0.0197 4.4–102.0
A P value 0.05 means significant differences by the Mann–Whitney U test between the study and control group patients. CI is confidence interval.
by lead chelating therapy. In contrast, a recent study than the basal BLS value and ten times higher than the
post-therapy BLS value of our patients. It is not strangesuggested that the lead chelating therapy did not improve
the urate excretion of CRI patients [24]. However, their that the urate excretion did not improve in their patients
after the chelating therapy [24]. In addition, that studypatients had lead poisoning rather than low-level envi-
ronmental lead exposure, because the BLS of these pa- had a small sample size (N  6) and no control group;
hence, it is not sufficiently rigorous in assessing environ-tients was up to 1568 g. The BLS value after chelation
therapy was up to 425 g, which was four times higher mental lead exposure.
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general population: The Cadmibel Study Group. N Engl J MedThe mechanism of improvement of urate excretion
327:151–156, 1992
after the removal of BLS is still unknown. Although 4. Payton M, Hu H, Sparrow D, Weiss ST: Low-level lead exposure
and renal function in the Normative Aging Study. Am J EpidemiolEDTA also removes some divalent cations such as cal-
140:821–829, 1994cium and copper from the body, to our knowledge there
5. Pirkle JL, Schwartz J, Landis JR, Harlan WR: The relationship
is no study of the relationship between urate excretion between blood lead levels and blood pressure and its cardiovascular
risk implications. Am J Epidemiol 121:246–258, 1985and these divalent cations. The most plausible explana-
6. Craswell PW, Price J, Boyle PD, et al: Chronic renal failure withtion is that, even at a low level, lead may affect urate
gout: A marker of chronic lead poisoning. Kidney Int 26:319–323,
excretion. There is a large body of evidence suggesting 1984
7. Campbell BC, Beattie AD, Moore MR, et al: Renal insufficiencythat heavy lead exposure or lead poisoning may cause
associated with excessive lead exposure. Br Med J 1:482–485, 1977proximal tubular dysfunction. The decreased urinary urate
8. Baker MD, Johnston JR, MacLatchy AE, Bezuidenhout BN:
excretion may be partially explained by a lead-induced The relationship of serum uric acid to subclinical blood lead. Rheu-
matol Rehabil 20:208–210, 1981inhibition of urate excretion [23, 25]. However, the
9. Lin JL, Lim PS: Elevated lead burden in Chinese patients withouthypotheses may not explain our observation in a general
occupational lead exposure. Miner Electrolyte Metab 18:1–5, 1992
population of low-level environmental lead exposure. 10. Lin JL, Huang PT: Body lead stores and urate excretion in men
with chronic renal disease. J Rheumatol 21:705–709, 1994Low-level chronic lead exposure may influence the renin-
11. Lin JL, Lim PS: Does lead play a role in the development of renalangiotensin system or endothelium-derived relaxing fac-
insufficiency in some patients with essential hypertension? J Hum
tor [26, 27] and cause a reduction of renal blood flow. Hypertens 8:495–500, 1994
12. Wise CM, Agudelo CA: Gouty arthritis and uric acid metabolism.In addition, some investigators have shown that patients
Curr Opin Rheumatol 8:248–254, 1996with chronic low-level lead exposure are likely to have
13. Isaksson B: Urinary nitrogen output as a validity test in dietary
a reduced renal blood flow that may predispose to an surveys. Am J Clin Nutr 33:4–5, 1980
14. Spencer K: Analytical reviews in clinical biochemistry: The estima-acquired defect of urate excretion [28]. Hence, lead may
tion of creatinine. Ann Clin Biochem 23:1–25, 1986directly or indirectly affect urate excretion, and the re-
15. James DR, Price CP: Problems associated with the measurement
moval of body lead may improve urate excretion and of uric acid using two enzyme-mediated reaction systems. Ann
Clin Biochem 21:405–410, 1984decrease serum urate levels in patients with CRI. How-
16. Rieselbach RE, Sorensen LB, Shelp WD, Steele TH: Dimin-ever, further study is needed to clarify a definite patho-
ished renal urate secretion per nephron as a basis for primary gout.
genesis. Ann Intern Med 73:359–366, 1970
17. Lin JL, Lim PS: Disappearance of immune deposits with EDTAIn conclusion, we postulate that the small amount of
chelation therapy in a case of IgA nephropathy. Am J Nephrollead absorbed from the environment plays a role in urate
12:457–460, 1992
excretion in patients with CRI. Importantly, the lead- 18. Lin JL, Shih FC: Reversible hypothyroidism with EDTA chelation
therapy in a patient with elevated lead burden and chronic renalinduced inhibition of urate excretion can be treated by
insufficiency. Nephrol Dial Transplant 12:364–365, 1997chelating therapies. If urate excretion can be improved,
19. Behringer D, Craswell P, Mohl C, et al: Urinary lead excretion
the episodes of gout should be reduced, and the progres- in uremic patients. Nephron 42:323–329, 1986
20. Batuman V, Maesaka JK, Haddad B, et al: The role of lead insive renal insufficiency in CRI patients be delayed or
gout nephropathy. N Engl J Med 304:520–523, 1981alleviated. This observation sheds more light on the
21. Colleoni N, D’Amico G: Chronic lead accumulation as a possible
treatment CRI patients with gout. Clearly, further study cause of renal failure in gouty patients. Nephron 44:32–35, 1986
22. Sanchez-Fructuoso AI, Torralbo A, Arroyo M, et al: Occultis needed to clarify the hypotheses.
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